Vaccinex Total Assets Over Time
| VCNX Stock | USD 3.62 0.02 0.56% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vaccinex Performance and Vaccinex Correlation. Vaccinex |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vaccinex. If investors know Vaccinex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vaccinex listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 7.42 | Revenue Per Share 0.318 | Quarterly Revenue Growth (0.81) | Return On Assets (4.96) | Return On Equity (7.59) |
The market value of Vaccinex is measured differently than its book value, which is the value of Vaccinex that is recorded on the company's balance sheet. Investors also form their own opinion of Vaccinex's value that differs from its market value or its book value, called intrinsic value, which is Vaccinex's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vaccinex's market value can be influenced by many factors that don't directly affect Vaccinex's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vaccinex's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vaccinex is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vaccinex's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Assets Analysis
Compare Vaccinex and related stocks such as Protara Therapeutics, Monopar Therapeutics, and Miromatrix Medical Total Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TARA | 84.8 M | 84.8 M | 84.8 M | 84.8 M | 84.8 M | 67.5 M | 43.5 M | 44 M | 23.5 M | 7 M | 203.2 M | 172.6 M | 113.3 M | 79 M | 92.2 M |
| MNPR | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.9 M | 9.9 M | 7.3 M | 13.4 M | 16.9 M | 20.5 M | 13.2 M | 7.3 M | 11.5 M |
| SRZN | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 62.1 M | 137.2 M | 89.4 M | 46.1 M | 83 M |
| SLRX | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 95.1 M | 63.2 M | 35 M | 10.4 M | 13.9 M | 24.9 M | 40.8 M | 14.7 M | 6.6 M | 6.3 M |
| SABS | 18 M | 18 M | 18 M | 18 M | 18 M | 18 M | 18 M | 18 M | 18 M | 18 M | 56.5 M | 79.4 M | 50.9 M | 83.9 M | 63.5 M |
| GOVX | 3.4 M | 1.6 M | 1.5 M | 2.8 M | 1.3 M | 1.3 M | 610.2 K | 490.2 K | 642 K | 468.9 K | 10.4 M | 11.8 M | 31.3 M | 9.3 M | 4.9 M |
| ERAS | 55.5 M | 55.5 M | 55.5 M | 55.5 M | 55.5 M | 55.5 M | 55.5 M | 55.5 M | 55.5 M | 55.5 M | 124.8 M | 501.4 M | 514.9 M | 395.3 M | 350.2 M |
| FBRX | 62.2 M | 62.2 M | 62.2 M | 62.2 M | 62.2 M | 62.2 M | 35.4 M | 92.1 M | 103.1 M | 7.7 M | 61.2 M | 43.3 M | 42 M | 39 M | 43.2 M |
| RNXT | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 1.9 M | 16.3 M | 7.3 M | 1.5 M | 1.4 M |
| ANEB | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 21.7 M | 15.6 M | 11.7 M | 4.1 M | 3.9 M |
| ELDN | 12 M | 12 M | 12 M | 32.3 M | 107.7 M | 68 M | 29.8 M | 20.9 M | 17 M | 10.9 M | 197.2 M | 170.5 M | 92.8 M | 125.9 M | 81.1 M |
Vaccinex and related stocks such as Protara Therapeutics, Monopar Therapeutics, and Miromatrix Medical Total Assets description
Total assets refers to the total amount of Vaccinex assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vaccinex books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.My Equities
My Current Equities and Potential Positions
| Vaccinex | VCNX |
| Classification | Pharmaceutical Products |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.62
Additional Tools for Vaccinex Stock Analysis
When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.